AR039669A1 - Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad - Google Patents

Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad

Info

Publication number
AR039669A1
AR039669A1 ARP030101430A ARP030101430A AR039669A1 AR 039669 A1 AR039669 A1 AR 039669A1 AR P030101430 A ARP030101430 A AR P030101430A AR P030101430 A ARP030101430 A AR P030101430A AR 039669 A1 AR039669 A1 AR 039669A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
aryl
heteroaryl
independently
Prior art date
Application number
ARP030101430A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR039669A1 publication Critical patent/AR039669A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable del mismo en la cual R1 es H, alquilo C1-6, alcanoilo C2-6 o carboarilalcoxi C7-11; cada uno de los R2 y R3 es, independientemente H, hidroxi, alquilo C1-6, alcoxi C1-6, halógeno, carboxamido, carboalcoxi C2-6, perfluoralquilo C1-6, ciano, alcansulfonamido C1-6,alcansulfonilo C1-6, alcanamido C1-6, amino, alquilamino C1-6, dialquilamino C1-6 por porción alquilo, perfluoralcoxi C1-6, alcanoiloxi C2-6, alcanoilo C2-6, aroilo C6-8, arilo C5-7, un grupo alquilarilo C6-13 con 5 a 7 átomos de C en la porción arilo, un grupo heteroarilo de 5 a 7 miembros o un grupo alquilheteroarilo de 6 a 13 miembros con 5 a 7 miembros en la porción heteroarilo, donde cualquier sustituyente R2 o R3 que tenga una porción arilo o heteroarilo puede estar optativamente sustituido en la porción arilo o heteroarilo con 1 a 3 sustituyentes independientemente seleccionados entre un átomo de halógeno, un grupo alquilo C1-6 o un grupo alcoxi C1-6; cada uno de R4 y R5 es, independientemente, H, o alquilo C1-6 R4 y R5, tomados junto con los C a los cuales están unidos forman una porción cíclica seleccionada entre un cicloalcano C4-8, cicloalqueno C4-8, alcano bicíclico formando puente de C5-10, alqueno bicíclico formando puente de C5-10, pirano o tiopirano, en los cuales el átomo de S está optativamente oxidado al sulfóxido o la sulfona, donde la porción cíclica formada por R4 y R5 puede estar optativamente sustituida con 1 a 3 sustituyentes independientemente seleccionados entre un átomo de halógeno, un grupo alquilo C1-6 o un grupo alcoxi C1-6; cada uno de R6 y R7 es, independientemente, H, o alquilo C1-6; n es 1 o 2 y una línea de puntos representa un doble enlace optativo.
ARP030101430A 2002-04-25 2003-04-24 Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad AR039669A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37559202P 2002-04-25 2002-04-25

Publications (1)

Publication Number Publication Date
AR039669A1 true AR039669A1 (es) 2005-03-02

Family

ID=29270669

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101430A AR039669A1 (es) 2002-04-25 2003-04-24 Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad

Country Status (28)

Country Link
US (2) US7129237B2 (es)
EP (1) EP1497293B1 (es)
JP (1) JP4537075B2 (es)
KR (1) KR101009269B1 (es)
CN (2) CN100376575C (es)
AR (1) AR039669A1 (es)
AT (1) ATE398127T1 (es)
AU (1) AU2003234213C1 (es)
BR (1) BR0309664A (es)
CA (1) CA2481321C (es)
CR (1) CR7510A (es)
CY (1) CY1108286T1 (es)
DE (1) DE60321559D1 (es)
DK (1) DK1497293T3 (es)
EC (1) ECSP045379A (es)
ES (1) ES2307937T3 (es)
HK (1) HK1069388A1 (es)
IL (1) IL164806A0 (es)
MX (1) MXPA04010372A (es)
NO (1) NO329505B1 (es)
NZ (1) NZ536115A (es)
PT (1) PT1497293E (es)
RU (1) RU2312866C2 (es)
SI (1) SI1497293T1 (es)
TW (1) TWI312781B (es)
UA (1) UA79782C2 (es)
WO (1) WO2003091250A1 (es)
ZA (1) ZA200409501B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical PREVENTIVE / REMEDY AGENTS FOR INCONTINENCE OF STRESS AND SELECETING METHOD THEREOF
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
AR051946A1 (es) * 2004-11-05 2007-02-21 Wyeth Corp Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
TW200635926A (en) * 2004-11-05 2006-10-16 Wyeth Corp Metabolites of ceratin [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2007025144A1 (en) * 2005-08-24 2007-03-01 University Of Illinois - Chicago 5-ht2c receptor agonists as anorectic agents
PE20070549A1 (es) * 2005-10-17 2007-06-15 Wyeth Corp Tetrahidroquinolinas, su sintesis e intermediarios
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
AR060086A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
EP1998782A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Methods for modulating bladder function
PE20080126A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
EP1998773A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware New therapeutic combinations for the treatment of depression
EP1998781A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Treatment of pain
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
WO2008144981A1 (fr) * 2007-05-25 2008-12-04 Topharman Shanghai Co., Ltd. Procédés et intermédiaires pour préparer une 4-acétyl-2,3,4,5-tétrahydro-1h-1,4-benzodiazépine
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
JP6198715B2 (ja) * 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
UA116216C2 (uk) 2012-09-14 2018-02-26 Еббві Дойчланд Гмбх Унд Ко. Кг Трициклічні хінолінові і хіноксалінові похідні
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015136091A1 (en) 2014-03-14 2015-09-17 AbbVie Deutschland GmbH & Co. KG Hexahydrodiazepinoquinolines carrying a substituted alkyl radical
US9573950B2 (en) 2014-03-14 2017-02-21 Abbvie Deutschland Gmbh & Co Kg Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US50300A (en) * 1865-10-03 John h
US422592A (en) * 1890-03-04 Reflector for incandescent lamps
US422657A (en) * 1890-03-04 Cane cutter or disintegrator
US3158619A (en) * 1962-06-14 1964-11-24 Searle & Co Certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3235564A (en) * 1964-03-27 1966-02-15 Searle & Co Intermediates to certain sulfur-containing ortho-fused polycyclic pyrazole derivatives
US3335134A (en) * 1964-04-02 1967-08-08 Sandoz Ag Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones
US3296252A (en) * 1964-04-02 1967-01-03 Sandoz Ag Tetracyclic diazepinone compounds
GB1120461A (en) * 1964-07-06 1968-07-17 Manuf Prod Pharma Derivatives of fluoreno-[1,9-ef]1,4-diazepine-1-oxide
US3417101A (en) * 1964-11-09 1968-12-17 American Home Prod Fused ring compounds
US3329676A (en) * 1964-11-09 1967-07-04 American Home Prod Fused 1, 4-diazepine ring systems
US3714149A (en) * 1969-11-03 1973-01-30 Upjohn Co Pyridobenzodiazepinones
US3914250A (en) * 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
DE2443567C3 (de) * 1974-09-12 1980-04-10 Hoechst Ag, 6000 Frankfurt U3,4,7,8-Hexahydro-(6H)-pyrido- [U3-ef] -1,5benzodiazepin-2-one, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SU930902A1 (ru) 1980-12-18 1982-10-15 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные тиено [3,2=в] индола
US4880814A (en) * 1987-11-13 1989-11-14 Abbott Laboratories 7-cycloalkyl naphthyridines
GB8812636D0 (en) 1988-05-27 1988-06-29 Glaxo Group Ltd Chemical compounds
JPH0240379A (ja) 1988-07-28 1990-02-09 Wakunaga Pharmaceut Co Ltd 新規キノロン誘導体
JPH02180885A (ja) 1988-09-01 1990-07-13 Glaxo Group Ltd ラクタム誘導体
EP0377238A1 (en) * 1988-12-22 1990-07-11 Duphar International Research B.V New annelated indolo (3,2-c)-lactams
CA2051697C (en) * 1989-06-09 1996-10-08 Malcolm Wilson Moon Heterocyclic amines having central nervous system activity
SE9500998D0 (sv) 1995-03-19 1995-03-19 Haakan Wilhelm Wikstroem New sulfone ester analogues of iso-clozapine and related structures: atypical neuroleptics
JPH10237073A (ja) 1996-02-02 1998-09-08 Sumitomo Pharmaceut Co Ltd 新規な置換グアニジン誘導体およびその製法
CA2195697A1 (en) 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
AU710825B2 (en) 1996-02-21 1999-09-30 Darwin Discovery Limited Quinolones and their therapeutic use
JP2000505451A (ja) 1996-02-21 2000-05-09 ダーウィン・ディスカバリー・リミテッド キノロン類およびこれらの治療的使用
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
EP1093372A4 (en) 1998-06-22 2004-09-29 Elan Pharm Inc CYCLIC AMINO ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF INHIBITING PEPTIDE RELEASE $ g (b) -AMYLOID AND / OR ITS SYNTHESIS USING THE SAME
SK8192001A3 (en) 1998-12-17 2001-12-03 American Home Prod 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivatives being 5ht2c agonists
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
AR023574A1 (es) 1999-04-23 2002-09-04 Pharmacia & Upjohn Co Llc Compuestos de azepinindol tetraciclico,composiciones farmaceuticas y el uso de dichos compuestos para preparar un medicamento, e intermediarios
US6552017B1 (en) 1999-06-15 2003-04-22 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
JP2001089461A (ja) 1999-09-24 2001-04-03 Konica Corp テトラヒドロナフトジアゼピン類の製造方法及びスクアリリウム染料の製造方法
US20030022918A1 (en) 2000-02-29 2003-01-30 Horak Ivan David Farnesyl protein transferase inhibitor combinations with an her2 antibody
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
US6414144B1 (en) * 2000-11-03 2002-07-02 Wyeth Process for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi] indole derivatives
AR031200A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031197A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta(b) diazepino(6,7,1-hi)indol
AR031201A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp /1,4/diazepino/6,7,1-jk/carbazoles y derivados
AR031202A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6916922B2 (en) * 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR031196A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
EP1330457B1 (en) 2000-11-03 2004-10-20 Wyeth Cyclopenta[b][1,4] diazepino[6,7,1-hi]indoles as 5ht2c antagonists
AR031199A1 (es) * 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
MXPA03005438A (es) * 2000-12-20 2004-05-05 Bristol Myers Squibb Co Pirioindoles substituidos como agonistas y antagonistas de serotonina.
DE60139511D1 (de) 2000-12-20 2009-09-17 Bristol Myers Squibb Co Substituierte pyrrolochinoline und pyridochinoline als serotonin- agonisten und- antagonisten
WO2003014125A1 (en) 2001-08-06 2003-02-20 Pharmacia & Upjohn Company Therapeutically useful tetracyclic ligands
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents

Also Published As

Publication number Publication date
DE60321559D1 (de) 2008-07-24
AU2003234213B2 (en) 2009-11-12
ATE398127T1 (de) 2008-07-15
RU2312866C2 (ru) 2007-12-20
EP1497293A1 (en) 2005-01-19
AU2003234213A1 (en) 2003-11-10
RU2004134361A (ru) 2005-05-10
TW200400038A (en) 2004-01-01
CN1955179A (zh) 2007-05-02
TWI312781B (en) 2009-08-01
CN1662533A (zh) 2005-08-31
NZ536115A (en) 2007-11-30
CR7510A (es) 2008-07-29
UA79782C2 (en) 2007-07-25
US20040009970A1 (en) 2004-01-15
KR20050000405A (ko) 2005-01-03
HK1069388A1 (en) 2005-05-20
JP4537075B2 (ja) 2010-09-01
AU2003234213C1 (en) 2010-05-20
IL164806A0 (en) 2005-12-18
ZA200409501B (en) 2007-04-25
CN1955179B (zh) 2010-07-14
SI1497293T1 (sl) 2008-10-31
EP1497293B1 (en) 2008-06-11
MXPA04010372A (es) 2005-02-03
JP2005529893A (ja) 2005-10-06
US7129237B2 (en) 2006-10-31
CA2481321C (en) 2012-01-03
NO329505B1 (no) 2010-11-01
DK1497293T3 (da) 2008-09-15
ECSP045379A (es) 2004-11-26
BR0309664A (pt) 2005-02-22
CN100376575C (zh) 2008-03-26
WO2003091250A1 (en) 2003-11-06
CA2481321A1 (en) 2003-11-06
KR101009269B1 (ko) 2011-01-18
CY1108286T1 (el) 2014-02-12
NO20044501L (no) 2005-01-18
US20070004707A1 (en) 2007-01-04
ES2307937T3 (es) 2008-12-01
US7687620B2 (en) 2010-03-30
PT1497293E (pt) 2008-09-05

Similar Documents

Publication Publication Date Title
AR039669A1 (es) Derivados de (1,4) diazepino (6,7,1/j) quinolina como agentes antipsicoticos y antiobesidad
AR039670A1 (es) Derivados de 1,2,3,4,7,8-hexahidro-6h-[1,4] diazepino [6,7,1j] quinolina como agentes antipsicoticos y antiobesidad
AR039668A1 (es) Derivados[1,4] diazocino [7,8,1-hi] indol como, agentes antipsicoticos y antiobesidad
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
AR046845A1 (es) Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
ES2071919T3 (es) Agentes antianginosos de pirazolopirimidina.
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR050169A1 (es) Compuesto para el tratamiento de trastornos inflamatorios
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
CO5680403A2 (es) Antagonistas de mchr1r
CO5540344A2 (es) Medicamentos
AR032361A1 (es) Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
AR033735A1 (es) Compuestos de alfa-aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ECSP045368A (es) "antagonistas de los receptores de trombina"
AR044342A1 (es) Derivados de bencimidazol
AR051946A1 (es) Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina
PE20010230A1 (es) Sulfonamidas como inhibidores de aspartil proteasa
AR049372A1 (es) Compuestos biciclicos de amina y composiciones farmaceuticas que los comprenden
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR035732A1 (es) Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados
AR038835A1 (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco
AR031196A1 (es) Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
AR027335A1 (es) Compuestos de piperidina-4-sulfonamida, proceso de preparacion de los mismos, y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal